Mutations in the alanine-glyoxylate amino transferase gene (AGXT) are responsible for primary hyperoxaluria type I, a rare disease characterized by excessive hepatic oxalate production that leads to renal failure. We generated a null mutant mouse by targeted mutagenesis of the homologous gene, Agxt, in embryonic stem cells. Mutant mice developed normally, and they exhibited hyperoxaluria and crystalluria. Approximately half of the male mice in mixed genetic background developed calcium oxalate urinary stones. Severe nephrocalcinosis and renal failure developed after enhancement of oxalate production by ethylene glycol administration. Hepatic expression of human AGT1, the protein encoded by AGXT, by adenoviral vector-mediated gene transfer in Agxt ؊/؊ mice normalized urinary oxalate excretion and prevented oxalate crystalluria. Subcellular fractionation and immunofluorescence studies revealed that, as in the human liver, the expressed wild-type human AGT1 was predominantly localized in mouse hepatocellular peroxisomes, whereas the most common mutant form of AGT1 (G170R) was localized predominantly in the mitochondria.
Mutations in the alanine-glyoxylate amino transferase gene (AGXT) are responsible for primary hyperoxaluria type I, a rare disease characterized by excessive hepatic oxalate production that leads to renal failure. We generated a null mutant mouse by targeted mutagenesis of the homologous gene, Agxt, in embryonic stem cells. Mutant mice developed normally, and they exhibited hyperoxaluria and crystalluria. Approximately half of the male mice in mixed genetic background developed calcium oxalate urinary stones. Severe nephrocalcinosis and renal failure developed after enhancement of oxalate production by ethylene glycol administration. Hepatic expression of human AGT1, the protein encoded by AGXT, by adenoviral vector-mediated gene transfer in Agxt ؊/؊ mice normalized urinary oxalate excretion and prevented oxalate crystalluria. Subcellular fractionation and immunofluorescence studies revealed that, as in the human liver, the expressed wild-type human AGT1 was predominantly localized in mouse hepatocellular peroxisomes, whereas the most common mutant form of AGT1 (G170R) was localized predominantly in the mitochondria.
gene therapy ͉ knockout mouse ͉ oxalate ͉ urolithiasis ͉ nephrocalcinosis P rimary hyperoxaluria type I (PH1) is a rare autosomal recessive disease caused by mutations in the alanine-glyoxylate aminotransferase gene (AGXT). AGT (or AGT1), the protein encoded by AGXT, is a key enzyme in glyoxylate detoxification. In humans, insufficient AGT activity in peroxisomes leads to increased conversion of glyoxylate to oxalate. Excessive renal excretion of oxalate causes loss of renal function because of calcium oxalate (CaOx) deposition. After renal failure, CaOx deposition becomes widespread and life-threatening unless liver and kidney transplantations are performed.
Although primary hyperoxaluria has been observed in a dog litter (1) , no genetic model for PH1 has been available, and the administration of ethylene glycol (EG) or oxalate to rats has remained the most widely used models to study the mechanisms of CaOx-related disease (2) .
The development of a laboratory animal deficient in the AGXT orthologous gene should provide a valuable tool for the study of PH1 and the development of new therapeutic approaches to the disease. We have cloned the mouse Agxt gene (also known as Agxt1), and we have characterized its tissue expression, genomic organization, and mapping (3). We report here the development of an Agxt knockout (KO) mouse that reproduces some key features of PH1. All homozygous Agxt Ϫ/Ϫ mice show severe hyperoxaluria, and approximately half of the males develop CaOx calculi in the urinary tract. Expression of human AGT in the liver of the Agxt Ϫ/Ϫ mice by adenoviral gene transfer reversed the phenotype of the Agxt Ϫ/Ϫ mice, providing a proof of principle for future work aimed at long-term correction of this disorder by gene therapy.
Results and Discussion
Targeted Disruption of the Agxt Gene and Generation of Agxt ؊/؊ Mice. Two embryonic stem (ES) cell clones had undergone homologous recombination with replacement of Agxt exons 4 -8 by the neoresistance cassette ( Fig. 1 a and b) . Agxt ϩ/Ϫ breeders, identified by PCR (Fig. 1c) , were intercrossed to generate the B6;129SvAgxt tm1Ull line (129B6-AgtKO for short), and then they were backcrossed with C57BL͞6 to generate the B6.129SvAgxt tm1Ull line (B6-AgtKO for short) .
Loss of Function of the Targeted Agxt Allele. Northern blotting showed lack of Agxt mRNA in livers from Agxt Ϫ/Ϫ mice, whereas the signal in heterozygous Agxt ϩ/Ϫ mice was reduced (Fig. 2a) . Western blotting showed that the Agxt Ϫ/Ϫ mice lacked the specific AGT band (Fig. 2b) as expected with a null allele. However, significant glyoxylate transaminase activity was present in liver extracts of Agxt Ϫ/Ϫ animals, mainly with alanine as a substrate (AGT activity) but also when serine was used as a substrate (SGT activity). AGT activity was significantly lower in Agxt Ϫ/Ϫ mice than in their wild-type littermates (1.2 Ϯ 0.1 vs. 2.1 Ϯ 0.1 mol/h per mg of protein, respectively; n ϭ 12 P Ͻ 0.01). Similarly, SGT activity was much lower in Agxt Ϫ/Ϫ mice than in their wild-type littermates (0.2 Ϯ 0.09 vs. 0.8 Ϯ 0.08 mol͞h per mg of protein, respectively; n ϭ 12, P Ͻ 0.0001). No significant differences in AGT activity were observed between Agxt Ϫ/Ϫ males and females (1.2 Ϯ 0.1 vs. 1.1 Ϯ 0.1 mol͞h per mg of protein, respectively; n ϭ 6) or between lines 129B6-AgtKO and B6-AgtKO (1.1 Ϯ 0.2 vs. 1.1 Ϯ 0.1 mol͞h per mg of protein, respectively; n ϭ 6). AGT activity in Agxt Ϫ/Ϫ mice was mainly of mitochondrial origin (see subcellular fractionation experiments below). In addition, glucagon administration failed to boost residual AGT activity in Agxt Ϫ/Ϫ mice (1.0 Ϯ 0.2 vs. 1.1 Ϯ 0.2 mol͞h per mg of protein, respectively; n ϭ 4). Subcellular fractionation showed that this residual activity in Agxt Ϫ/Ϫ mice was predominantly mitochondrial in origin, and it must represent the contribution of other hepatic aminotransferases. Whereas human AGT1 is predominantly localized in the peroxisome, the mouse Agxt gene is transcribed into two differ-ent mRNA molecules, coding for mitochondrial and peroxisomal variants (3). In fact, rodent AGT1 is also known as serinepyruvate aminotransferase (SPT) because the mitochondrial form participates in gluconeogenesis from serine, whereas the conversion of glyoxylate to glycine takes place largely in peroxisomes. Another alanine-glyoxylate aminotransferase (AGT2) is abundant in mouse liver mitochondria (4). No differences were observed in growth and development of Agxt Ϫ/Ϫ mice compared with their heterozygous or wild-type littermates. Similarly, histological analysis of brain, lung, heart, stomach, liver, spleen, pancreas, small and large bowel, gonads, and bone revealed no differences among the various genotypes. Kidneys from Agxt Ϫ/Ϫ mice (129B6-AgtKO) were more thoroughly studied, with a total of 60 animals analyzed and five consecutive sections observed per sample. They showed almost normal histology with hematoxylin͞eosin staining, with only occasional dilation of terminal collecting ducts at the papilla. Staining for CaOx revealed occasional small deposits both within the lumen and the epithelium͞interstitium (Fig. 3a) , and these parenchymal deposits were generally seen in relation with distal collecting ducts at the papilla. Such deposits were observed in only five Agxt Ϫ/Ϫ animals (two males and three females). It could be speculated that the high glomerular filtration rate of the mouse, relative to its body weight (5), might make mice less prone to renal crystal deposition, despite high urinary oxalate excretion. No deposits were found in the kidneys of 60 Agxt ϩ/ϩ control mice.
Gluconeogenesis in the Agxt ؊/؊ Mice. Blood glucose levels after 16-h fasting were similar in Agxt Ϫ/Ϫ mice (B6-AgtKO) and Agxt ϩ/ϩ controls (93.7 Ϯ 16.3 vs. 82.3 Ϯ 13.9; n ϭ 6 per group, t test, P ϭ 0.111). No differences were detected in the glycemic response to serine administration (ANOVA, P ϭ 0.2, 0.6, 0.1, 0.2 for values at 30, 60, 90, and 120 min after serine overload, respectively), consistent with the reported small contribution of L-serine to gluconeogenesis through SPT͞AGT in the rat, where L-serine enters the neoglucogenesis pathway mainly through serine dehydratase (6) . mice from the same litters of the B6-AgtKO line (n ϭ 10 in each group) is shown in Table 1 . Agxt Ϫ/Ϫ mice were hyperoxaluric with respect to controls (1.20 Ϯ 0.26 vs. 0.34 Ϯ 0.08 mM among males and 1.02 Ϯ 0.18 vs. 0.31 Ϯ 0.08 among females; P Ͻ 0.0001). Male Agxt Ϫ/Ϫ mice showed higher urinary oxalate concentration than did females of the same genotype (1.20 Ϯ 0.26 vs. 1.02 Ϯ 0.18; P Ͻ 0.05). Gender differences in urinary concentration and 24-h excretion of oxalate are well documented in humans (7) and rats (8) . There is evidence suggesting that this gender variation is caused by the hormonal regulation of glycolate oxidase activity (9). Our results are consistent with males having a higher NcoI band, as seen in the clone labeled ( * ). WT, wild-type fragments; KO, mutant fragments. (c) Genotyping of tail tip DNA by PCR analysis, using the wild-type-specific primer in exon 4 and the mutant-specific primer in the neoresistance cassette, together with a common forward primer complementary to exon 3. Wild-type and mutated alleles are detected in a three-primer PCR as 0.6-kb and 0.4-kb products, respectively. glyoxylate load, which in the absence of AGT1, results in more robust elevations of oxalate production than in females.
Urine glycolate values, carried out in samples pooled from four different animals, were also higher in Agxt Ϫ/Ϫ than in Agxt ϩ/ϩ mice (0.125 vs. 0.035 mM and glycolate͞creatinine ratios of 0.053 vs. 0.015, respectively).
No significant differences in analyte concentrations were detected among 3-and 6-month-old animals of the same genotype. Similar results were obtained with mice from the 129B6-AgtKO line for all of the biochemical parameters measured (data not shown). No detectable differences were seen between Agxt Ϫ/Ϫ and Agx ϩ/ϩ mice in the following parameters measured with urinalysis strips: specific gravity, pH, leukocytes, nitrate, protein, glucose, ketones, urobilinogen, and bilirubin. The values were within the normal limits in human urine, for which the test has been validated, with the only exception being proteinuria. Both Agxt Ϫ/Ϫ and control mice showed mild proteinuria (1ϩ) in the urinalysis strips, which is consistent with the physiological protein concentration of mouse urine. Occasional mice with urinary bladder stones yielded positive strip tests for hemoglobin and red blood cells. Sediment Analysis. CaOx crystals, mostly with the tetrahedric appearance typical of CaOx dihydrate (COD) (Fig. 3c) , were observed in all Agxt Ϫ/Ϫ mice at some point during the 5-day follow-up. Oxalate crystal abundance varied substantially among the mice and also within the same mouse on different days. On average, three samples during the week-long study showed notable crystalluria in these mice, with numerous clusters and occasional microliths. On the other hand, no calcium oxalate crystals were observed in the Agxt ϩ/ϩ mice during the 5 days of the urine sediment study. Occasional calcium phosphate crystals were observed in both Agxt Ϫ/Ϫ and Agxt ϩ/ϩ mice.
Development of Urinary Bladder Stones. Sixty-two of the 118 male Agxt Ϫ/Ϫ mice (129B6-AgtKO) killed after 6 months of age contained stones in the urinary bladder (53%), whereas none of the females studied (n ϭ 225) had urinary stones. Interestingly, none of the B6-AgtKO males, with pure C57BL/6 background, showed urolithiasis (n ϭ 125). A large majority of human urinary stones contain CaOx as the principal component (10) , and the incidence of idiopathic CaOx stone disease in men is three times higher than in women (11) . Similar gender differences have also been reported in EG-induced lithiasis in rats (12) . Although CaOx supersaturation is a key component, the pathogenesis of kidney stone disease is very complex (13). We did not find significant differences in ionic composition of the urine, other than oxalate, between male and female Agxt Ϫ/Ϫ mice in both genetic backgrounds. Some 129 mice have been observed to present glycolipoprotein calculi (14) . Further investigations of the two lines of mice reported here might yield important clues about the basic mechanisms of stone disease.
Physicochemical Analysis of Urinary Stones. Two main types of calculi were observed in 129B6-AgtKO homozygous males. In 28 of these animals (45%), stones were single, amber-colored calculi, ranging in size between 2 and 5 mm (Fig. 3d) . In 16 mice (26%), multiple whitish stones were present, measuring 0.1-2 mm each (Fig. 3e) . In the remaining 18 cases (29%), urinary stones showed mixed features. Three samples from each of these morphological categories were chosen for x-ray diffraction analysis. The most common stones showed spectra characteristic of COD (Fig. 3f ) , whereas the second type corresponded to calcium oxalate monohydrate (COM) (Fig. 3g) , and the third type was composed of COD with variable amounts of COM (10-40%).
Effect of EG Challenge. EG is a well known precursor of glycolate that provides an overload of glyoxylate, the substrate of AGT. Previous studies have shown that up to 1% EG is well tolerated by wild-type mice, which are capable of eliminating high concentrations of oxalate in the urine without apparent renal damage (15) (16) (17) . Serum, urine, and kidneys were studied in six Agxt Ϫ/Ϫ male mice (B6-AgtKO) and six Agxt ϩ/ϩ controls that had received 0.7% EG in the drinking water for 3 weeks. EG intake was similar in both groups (average daily consumption of 5.17 Ϯ 1.84 and 5.48 Ϯ 2.12 ml per mouse, respectively). Urine oxalate excretion, assessed during the third week of treatment, was significantly higher in Agxt Ϫ/Ϫ mice than the controls (6.39 Ϯ 1.77 vs. 1.80 Ϯ 0.37 mol/24 h; P Ͻ 0.0001). In addition, all kidneys from Agxt Ϫ/Ϫ mice showed a variable degrees of nephrocalcinosis at the end of the study (Fig. 3b) , with percentages of the area occupied by CaOx deposits ranging from 0.05% (mild nephrocalcinosis, observed in one mouse) to 5% (severe nephrocalcinosis, observed in three mice). Both plasma oxalate and creatinine concentrations were elevated among the mice with severe nephrocalcinosis (16 Ϯ 7 and 108 Ϯ 42 M, respectively), with creatinine clearance reduced to 2.8 Ϯ 1.4 ml͞h (vs. 10.6 Ϯ 2.1 ml͞h for the control group). None of the Agxt ϩ/ϩ control mice examined had nephrocalcinosis, and their plasma oxalate and creatinine concentrations were normal (4 Ϯ 2 and 17 Ϯ 8.7 M, respectively).
Effect of AGXT Gene Transfer. Western blotting of AGT on liver homogenates from untreated Agxt Ϫ/Ϫ mice (B6-AgtKO) showed (Fig. 4a) . Concomitantly, AGT activity in liver homogenates increased from preinjection levels of 1.02 Ϯ 0.03 mol͞h per mg of protein to 2.6 Ϯ 0.8 and 2.3 Ϯ 0.9 mol͞h per mg of protein, 7 days after injections of Ad-AGXT and Ad-AGXT LRM , respectively (Fig. 4b) . These values were not significantly different from those in the Agxt ϩ/ϩ controls (2.2 Ϯ 0.8 mol͞h per mg of protein). Hepatic AGT activity did not increase after the injection of Ad-LacZ.
Localization of AGT and AGT LRM in Subcellular Fractions After Adenoviral Gene Transfer. Although both peroxisome-and mitochondria-enriched fractions were positive in liver homogenates of mice treated with Ad-AGXT and Ad-AGXT LRM , the immunoreactive band was much more intense in the peroxisomeenriched fraction when the wild-type AGT was expressed (Fig.  4a) . In contrast, the mitochondrial fraction exhibited a more intense immunoreactive band when AGT LRM was expressed. In Agxt ϩ/ϩ mice, AGT activity was distributed bimodally to the peroxisome-and mitochondria-enriched fractions. Specific AGT activity, relative to that of the liver homogenate, was 1.5 and 1.25, respectively, in the peroxisome-and mitochondria-enriched fractions (Fig. 4b) . In untreated Agxt Ϫ/Ϫ mice, the relative specific AGT activities were 0.5 Ϯ 0.01 in the peroxisomeenriched fraction and 3.1 Ϯ 0.32 in the mitochondria-enriched fraction. Seven days after the injection of Ad-AGXT and Ad-AGXT LRM , the specific AGT activity in liver homogenates increased by Ϸ155% and Ϸ125%, respectively. In mice receiving Ad-AGXT, the relative specific activities in the peroxisome-and mitochondria-enriched fractions were 3.2 Ϯ 0.8 and 0.8 Ϯ 0.04, respectively. In contrast, after the injection of Ad-AGXT LRM , the relative specific activities in the peroxisome-and mitochondria-enriched fractions were 1.1 Ϯ 0.4 and 2.8 Ϯ 0.7, respectively. Enrichment of peroxisomes and mitochondria was demonstrated by enhancement of the specific activity of catalase and succinate dehydrogenase in the respective fractions of the liver homogenate (Fig. 4c) and also by transmission electron microscopy ( Fig.  4 d and e) .
Intracellular Localization of AGT and AGT LRM After Adenoviral Gene
Transfer. After transfer of either the wild-type human AGXT or the mutant AGXT LRM gene using the respective recombinant adenoviral vector, hepatocytes stained positive for AGT (Fig. 5  c, g, k, and o, which is published as supporting information on the PNAS web site). Wild-type AGT colocalized largely with the peroxisomal marker PEX19 (Fig. 5d ). There was also some colocalization with the mitochondrial marker, but largely the green and red pixels were nonoverlapping (Fig. 5h) . In contrast, colocalization of AGT LRM with PEX19 was minimal (Fig. 5l) , whereas it significantly colocalized with mitochondria (Fig. 5p) . The above findings are consistent with the previous reports showing that the AGXT LRM mutant enzyme is mistargeted to the mitochondria in hepatocytes of PH1 patients (18) .
Urinary Oxalate Concentrations and Crystalluria. In urine samples collected from the Agxt Ϫ/Ϫ mice (B6-AgtKO) before administration of adenoviral vectors, oxalate concentrations ranged from 0.8 to 2.0 mM (1.4 Ϯ 0.7, mean Ϯ SD), which were significantly higher than in 129Sv (0.13 Ϯ 0.05) or C57BL͞6 (0.15 Ϯ 0.06) controls (n ϭ 12, P Ͻ 0.001). Urine sediments of the Agxt Ϫ/Ϫ mice routinely exhibited oxalate crystals. Seven and 14 days after injection of 2 ϫ 10 9 infectious units of Ad-AGXT, urinary oxalate concentrations in the Agxt Ϫ/Ϫ mice were reduced significantly to 0.1 Ϯ 0.07 and 0.11 Ϯ 0.06, respectively (n ϭ 6, P Ͻ 0.001). Furthermore, oxalate crystals were not found in urine sediments of the Ad-AGXT-treated Agxt Ϫ/Ϫ mice. Thirty days after Ad-AGXT injection, urinary oxalate concentrations of the treated Agxt Ϫ/Ϫ mice increased to 0.55 Ϯ 0.52, suggesting gradual loss of the transgene. There was no significant reduction in urinary oxalate excretion after injection of Ad-AGXT LRM or the control Ad-LacZ vector.
PH1 is a disease associated with overproduction of oxalate by hepatocytes. Thus, correction of a majority of hepatocytes will probably be needed (19) . We used recombinant adenoviral vectors because of their high efficiency in transferring genes to hepatocytes in vivo, to establish the principle that gene therapy could potentially be an effective therapeutic modality for PH1. Alternative vectors that integrate into the host genome and can be administered repeatedly (20) are needed to overcome well known limitations of adenoviral vectors. In addition to the obvious utility of this mouse model in developing gene and cell-based therapies, the integrating vectors will permit stable expression in the liver of Agxt Ϫ/Ϫ mice of different mutant forms of human AGXT that are associated with PH1. Such authentic models of human PH1 could be potentially useful in the discovery and evaluation of small molecules that may modify the misfolding of mutant but catalytically active enzyme proteins, thereby enabling them to be targeted to peroxisomes (21) . and succinate dehydrogenase (mitochondrial marker) activities in liver homogenate (H), and mitochondrial (M) and peroxisomal (P) fractions from Agxt Ϫ/Ϫ mice are shown (n ϭ 6). The specific activity of catalase in the peroxisomal fraction, relative to that in the liver homogenate, was Ϸ60, whereas the mitochondrial fraction was depleted to a relative specific activity of 0.8. Relative specific activity of succinate dehydrogenase was Ϸ6 in the mitochondrial fraction and was depleted to 0.2 in the peroxisomal fraction. 
Transfer of Wild-Type and Mutant Human AGXT into the Livers of
Agxt ؊/؊ Mice. Adenovirus vectors expressing wild-type human AGXT (Ad-AGXT) and a minor allele of AGXT that carries a P11L and an I340M polymorphism as well as a G170R amino acid replacement (Ad-AGXT LRM ) were generated. We used BD Adeno-X Expression Systems (BD Biosciences, San Jose, CA) to generate the adenoviral vectors, according to the manufacturer's protocol. Infectious adenoviral vectors were harvested by cell lysis and purified by CsCl gradient centrifugation. Agxt Ϫ/Ϫ mice (B6-AgtKO) were injected with 1 ϫ 10 11 particles of Ad-AGXT (Ϸ2 ϫ 10 9 infectious units) through the tail vein. Control Agxt Ϫ/Ϫ mice received 2 ϫ 10 9 infectious units of an adenovector (Ad-LacZ) expressing Escherichia coli ␤-galactosidase. Urine samples were collected on two consecutive nights before adenovirus vector injections and 7, 14, and 30 days after injection. In six additional mice, after the urine collection on day 7, the mice were killed for assaying hepatic AGT activity, examining liver histology, and determining the subcellular localization of the expressed human AGT. Subcellular Fractionation. Mitochondria and peroxisome-enriched fractions of liver homogenates were prepared as described in ref. 26 . To determine the relative enrichment of the fractions by peroxisomes and mitochondria, we assayed catalase (27) and succinate dehydrogenase activities (28), and we analyzed representative fractions by electron microscopy (29) . 9 infectious units of recombinant Ad-AGXT, and group c received Ad-AGXT LRM . In each group, two mice were killed at days 5 and 8 after injection. Primary hepatocytes were isolated by collagenase perfusion in situ (30) and cultured on collagen-coated glass coverslips. For evaluation of colocalization with mitochondria, the cells were incubated for 15 min at 37°C with 200 nM MitoTracker Red (Molecular Probes, Eugene, OR). After a 15-min fixation in 4% paraformaldehyde and permeabilization with 0.2% Triton X-100, the cells were incubated with rabbit anti-human AGT and an FITC-conjugated goat anti-rabbit IgG (Sigma). To determine colocalization with peroxisomes, the cells were double-stained with chicken anti-PEX19 PxF (31) antibody (Abcam). AGT was visualized with the FITC goat anti-rabbit as above, and peroxisomes were visualized by using rhodamine-labeled goat anti-chicken (Abcam). All incubations with the antibodies were performed at room temperature for 1 h in PBS containing 2% BSA, and the cells were washed in PBS containing 2% BSA three times after each incubation. The coverslips were mounted with DAPI medium (Vector Laboratories, Burlingame, CA). Images were taken with a ϫ100 objective in a confocal laser-scanning microscope (Zeiss, Chicago, IL).
